• Aebi C, Theiler F, Aebischer CC, Schoeni MH 2000 Autoantibodies directed against bactericidal/permeability-increasing protein in patients with cystic fibrosis: association with microbial respiratory tract colonization. Pediatr. Infect. Dis. J. 19: 207-212.

• Aichele D, Schnare M, Saake M, Rollinghoff M, Gessner A 2006 Expression and antimicrobial function of bactericidal permeability-increasing protein in cystic fibrosis patients. Infect. Immun. 74: 4708-4714. *

• Alexander S, Bramson J, Foley R, Xing Z 2004 Protection from endotoxemia by adenoviral-mediated gene transfer of human bactericidal/permeability-increasing protein. Blood 103: 93-99. *

• Allenby G, Bocquel MT, Saunders M, Kazmer S, Speck J, Rosenberger M, Lovey A, Kastner P, Grippo JF, Chambon P, et al 1993 Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc. Natl. Acad. Sci. U.S.A. 90: 30-34. *

• Andrault JB, Gaillard I, Giorgi D, Rouquier S 2003 Expansion of the BPI family by duplication on human chromosome 20: characterization of the RY gene cluster in 20q11.21 encoding olfactory transporters/antimicrobial-like peptides. Genomics 82: 172-184. *

• Ardiles LG, Valderrama G, Moya P, Mezzano SA 1997 Incidence and studies on antigenic specificities of antineutrophil-cytoplasmic autoantibodies (ANCA) in poststreptococcal glomerulonephritis. Clin. Nephrol. 47: 1-5.

• Audrain MA, Sesboue R, Baranger TA, Elliott J, Testa A, Martin JP, Lockwood CM, Esnault VL 2001 Analysis of anti-neutrophil cytoplasmic antibodies (ANCA): frequency and specificity in a sample of 191 homozygous (PiZZ) alpha1-antitrypsin-deficient subjects. Nephrol. Dial. Transplant. 16: 39-44. *

• Bartoli F, Angotti C, Fatini C, Conforti ML, Guiducci S, Blagojevic J, Melchiorre D, Fiori G, Generini S, Damjanov N, Rednic S, Pignone A, Castellani S, Abbate R, Matucci Cerinic M 2007 Angiotensin-converting enzyme I/D polymorphism and macrovascular disease in systemic sclerosis. Rheumatology (Oxford) 46: 772-775. *

• Beamer LJ 2003 Structure of human BPI (bactericidal/permeability-increasing protein) and implications for related proteins. Biochem. Soc. Trans. 31: 791-794. *

• Beamer LJ, Carroll SF, Eisenberg D 1999 The three-dimensional structure of human bactericidal/permeability-increasing protein: implications for understanding protein-lipopolysaccharide interactions. Biochem. Pharmacol. 57: 225-229. *

• Beamer LJ, Carroll SF, Eisenberg D 1998 The BPI/LBP family of proteins: a structural analysis of conserved regions. Protein Sci. 7: 906-914. *

• Belyaeva OV, Johnson MP, Kedishvili NY 2008 Kinetic analysis of human enzyme RDH10 defines the characteristics of a physiologically relevant retinol dehydrogenase. J. Biol. Chem. 283: 20299-20308. *

• Bingle CD, Craven CJ 2002 PLUNC: a novel family of candidate host defence proteins expressed in the upper airways and nasopharynx. Hum. Mol. Genet. 11: 937-943. *

• Bingle CD, Craven CJ 2004 Meet the relatives: a family of BPI- and LBP-related proteins. Trends Immunol. 25: 53-55. *

• Bingle CD, Gorr SU 2004 Host defense in oral and airway epithelia: chromosome 20 contributes a new protein family. Int. J. Biochem. Cell. Biol. 36: 2144-2152. *

• Bingle CD, LeClair EE, Havard S, Bingle L, Gillingham P, Craven CJ 2004 Phylogenetic and evolutionary analysis of the PLUNC gene family. Protein Sci. 13: 422-430. *

• Bohn G, Allroth A, Brandes G, Thiel J, Glocker E, Schaffer AA, Rathinam C, Taub N, Teis D, Zeidler C, Dewey RA, Geffers R, Buer J, Huber LA, Welte K, Grimbacher B, Klein C 2007 A novel human primary immunodeficiency syndrome caused by deficiency of the endosomal adaptor protein p14. Nat. Med. 13: 38-45. *

• Bokarewa MI, Jin T, Tarkowski A 2003 Intraarticular release and accumulation of defensins and bactericidal/permeability-increasing protein in patients with rheumatoid arthritis. J. Rheumatol. 30: 1719-1724.

• Bombieri C, Bonizzato A, Castellani C, Assael BM, Pignatti PF 2005 Frequency of large CFTR gene rearrangements in Italian CF patients. Eur. J. Hum. Genet. 13: 687-689. *

• Brooks CJ, King WJ, Radford DJ, Adu D, McGrath M, Savage CO 1996 IL-1 beta production by human polymorphonuclear leucocytes stimulated by anti-neutrophil cytoplasmic autoantibodies: relevance to systemic vasculitis. Clin. Exp. Immunol. 106: 273-279. *

• Brownlee AA, Lockwood CM 1999 Heat treatment of normal human sera reveals antibodies to bactericidal permeability-inducing protein (BPI). Clin. Exp. Immunol. 117: 183-189. *

• Bulow E, Gullberg U, Olsson I 2000 Structural requirements for intracellular processing and sorting of bactericidal/permeability-increasing protein (BPI): comparison with lipopolysaccharide-binding protein. J. Leukoc. Biol. 68: 669-678. *

• Burrows NP, Zhao MH, Norris PG, Lockwood CM 1996 ANCA associated with Behcet's disease. J. R. Soc. Med. 89: 47P-48P. *

• Calafat J, Janssen H, Knol EF, Malm J, Egesten A 2000 The bactericidal/permeability-increasing protein (BPI) is membrane-associated in azurophil granules of human neutrophils, and relocation occurs upon cellular activation. APMIS 108: 201-208.

• Calafat J, Janssen H, Tool A, Dentener MA, Knol EF, Rosenberg HF, Egesten A 1998 The bactericidal/permeability-increasing protein (BPI) is present in specific granules of human eosinophils. Blood 91: 4770-4775. *

• Calvano SE, Thompson WA, Marra MN, Coyle SM, de Riesthal HF, Trousdale RK, Barie PS, Scott RW, Moldawer LL, Lowry SF 1994 Changes in polymorphonuclear leukocyte surface and plasma bactericidal/permeability-increasing protein and plasma lipopolysaccharide binding protein during endotoxemia or sepsis. Arch. Surg. 129: 220-226.

• Canny G, Cario E, Lennartsson A, Gullberg U, Brennan C, Levy O, Colgan SP 2006 Functional and biochemical characterization of epithelial bactericidal/permeability-increasing protein. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G557-G567. *

• Canny G, Colgan SP 2005 Events at the host-microbial interface of the gastrointestinal tract. I. Adaptation to a microbial world: role of epithelial bactericidal/permeability-increasing protein. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G593-G597. *

• Canny G, Levy O, Furuta GT, Narravula-Alipati S, Sisson RB, Serhan CN, Colgan SP 2002 Lipid mediator-induced expression of bactericidal/ permeability-increasing protein (BPI) in human mucosal epithelia. Proc. Natl. Acad. Sci. U.S.A. 99: 3902-3907. *

• Canny GO, Trifonova RT, Kindelberger DW, Colgan SP, Fichorova RN 2006 Expression and function of bactericidal/permeability-increasing protein in human genital tract epithelial cells. J. Infect. Dis. 194: 498-502. *

• Carlsson M, Eriksson L, Erwander I, Wieslander J, Segelmark M 2003 Pseudomonas-induced lung damage in cystic fibrosis correlates to bactericidal-permeability increasing protein (BPI)-autoantibodies. Clin. Exp. Rheumatol. 21: S95-S100.

• Carlsson M, Eriksson L, Pressler T, Kornfalt R, Mared L, Meyer P, Wiik A, Wieslander J, Segelmark M 2007 Autoantibody response to BPI predict disease severity and outcome in cystic fibrosis. J. Cyst. Fibros. 6: 228-233.

• Chen M, Zhao M, Zhang Y, Wang H 2002 Antigens of antineutrophil cytoplasmic autoantibodies in recognizing a novel neutrophil granule antigen in lupus nephritis and its association with photosensitivity and oral ulceration. Zhonghua Nei Ke Za Zhi 41: 766-768.

• Chen M, Zhao MH, Zhang YK, Wang HY 2005 Antineutrophil cytoplasmic autoantibodies in patients with systemic lupus erythematosus recognize a novel 69 kDa target antigen of neutrophil granules. Nephrology (Carlton) 10: 491-495. *

• Cooper T, Savige J, Nassis L, Paspaliaris B, Neeson P, Neil J, Knight KR, Daskalakis M, Doery JC 2000 Clinical associations and characterisation of antineutrophil cytoplasmic antibodies directed against bactericidal/permeability-increasing protein and azurocidin. Rheumatol. Int. 19: 129-136. *

• Dentener MA, Francot GJ, Buurman WA 1996 Bactericidal/permeability-increasing protein, a lipopolysaccharide-specific protein on the surface of human peripheral blood monocytes. J. Infect. Dis. 173: 252-255.

• Dorlochter L, Carlsson M, Olafsdottir EJ, Roksund OD, Rosendahl K, Fluge G 2004 Anti-neutrophil cytoplasmatic antibodies and lung disease in cystic fibrosis. J. Cyst. Fibros. 3: 179-183.

• Dunn AC, Walmsley RS, Dedrick RL, Wakefield AJ, Lockwood CM 1999 Anti-neutrophil cytoplasmic autoantibodies (ANCA) to bactericidal/permeability-increasing (BPI) protein recognize the carboxyl terminal domain. J. Infect. 39: 81-87.

• Eckert M, Wittmann I, Rollinghoff M, Gessner A, Schnare M 2006 Endotoxin-induced expression of murine bactericidal permeability/increasing protein is mediated exclusively by Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta-dependent pathways. J. Immunol. 176: 522-528. *

• Elkayam O, Levartovsky D, Brautbar C, Yaron M, Burke M, Vardinon N, Caspi D 1998 Clinical and immunological study of 7 patients with minocycline-induced autoimmune phenomena. Am. J. Med. 105: 484-487. *

• Elsbach P 1998 The bactericidal/permeability-increasing protein (BPI) in antibacterial host defense. J. Leukoc. Biol. 64: 14-18. *

• Elsbach P 1994 Bactericidal permeability-increasing protein in host defence against gram-negative bacteria and endotoxin. Ciba Found. Symp. 186: 176-187.

• Elsbach P, Weiss J 1993 Bactericidal/permeability increasing protein and host defense against gram-negative bacteria and endotoxin. Curr. Opin. Immunol. 5: 103-107.

• Elsbach P, Weiss J 1998 Role of the bactericidal/permeability-increasing protein in host defence. Curr. Opin. Immunol. 10: 45-49.

• Elsbach P, Weiss J 1995 Prospects for use of recombinant BPI in the treatment of gram-negative bacterial infections. Infect. Agents Dis. 4: 102-109.

• Elsbach P, Weiss J 1993 The bactericidal/permeability-increasing protein (BPI), a potent element in host-defense against gram-negative bacteria and lipopolysaccharide. Immunobiology 187: 417-429.

• Elsbach P, Weiss J, Doerfler M, Shu C, Kohn F, Ammons WS, Kung AH, Meszaros KK, Parent JB 1994 The bactericidal/permeability increasing protein of neutrophils is a potent antibacterial and anti-endotoxin agent in vitro and in vivo. Prog. Clin. Biol. Res. 388: 41-51.

• Elzouki AN, Eriksson S, Lofberg R, Nassberger L, Wieslander J, Lindgren S 1999 The prevalence and clinical significance of alpha 1-antitrypsin deficiency (PiZ) and ANCA specificities (proteinase 3, BPI) in patients with ulcerative colitis. Inflamm. Bowel Dis. 5: 246-252. *

• Emmi L, Chatzipetrou A 2005 Bactericidal/permeability-increasing protein antineutrophil cytoplasmic antibodies (ANCA) and associated diseases: clinical relevance of an emerging ANCA target antigen. Ann. Ital. Med. Int. 20: 205-208. *

• Fang WH, Yao YM, Shi ZG, Yu Y, Wu Y, Lu LR, Sheng ZY 2001 Effect of recombinant bactericidal/permeability-increasing protein on endotoxin translocation and lipopolysaccharide-binding protein/CD14 expression in rats after thermal injury. Crit. Care Med. 29: 1452-1459.

• Feng X, Peng ZH, Di W, Li XY, Rochette-Egly C, Chambon P, Voorhees JJ, Xiao JH 1997 Suprabasal expression of a dominant-negative RXR alpha mutant in transgenic mouse epidermis impairs regulation of gene transcription and basal keratinocyte proliferation by RAR-selective retinoids. Genes Dev. 11: 59-71. *

• Folwaczny C, Jochum M, Noehl N, Schnettler D, Loeschke K, Fricke H 1998 p-ANCA target antigens in ulcerative colitis. Z. Gastroenterol. 36: 625-633.

• Gallego O, Belyaeva OV, Porte S, Ruiz FX, Stetsenko AV, Shabrova EV, Kostereva NV, Farres J, Pares X, Kedishvili NY 2006 Comparative functional analysis of human medium-chain dehydrogenases, short-chain dehydrogenases/reductases, and aldo-keto reductases with retinoids. Biochem. J. 399: 101-109. *

• Geraldes P, Yamagata M, Rook SL, Sassa Y, Ma RC, Clermont A, Gao B, Aiello LP, Feener EP, King GL 2007 Glypican 4, a membrane binding protein for bactericidal/permeability-increasing protein signaling pathways in retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 48: 5750-5755. *

• Giroir BP, Quint PA, Barton P, Kirsch EA, Kitchen L, Goldstein B, Nelson BJ, Wedel NJ, Carroll SF, Scannon PJ 1997 Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis. Lancet 350: 1439-1443. *

• Glas J, Torok HP, Tonenchi L, Hamann S, Malachova O, Euba A, Folwaczny C, Folwaczny M 2006 A645G (Lys216Glu) polymorphism of the bactericidal/permeability-increasing protein gene in periodontal disease. Int. J. Immunogenet. 33: 255-260. *

• Grypiotis P, Cozzi F, Ruffatti A 2004 Autoantibodies to bactericidal/permeability-increasing protein and cathepsin G in systemic sclerosis. J. Rheumatol. 31: 1468-1469.

• Gubern C, Lopez-Bermejo A, Biarnes J, Vendrell J, Ricart W, Fernandez-Real JM 2006 Natural antibiotics and insulin sensitivity: the role of bactericidal/permeability-increasing protein. Diabetes 55: 216-224. *

• Guidez F, Parks S, Wong H, Jovanovic JV, Mays A, Gilkes AF, Mills KI, Guillemin MC, Hobbs RM, Pandolfi PP, de The H, Solomon E, Grimwade D 2007 RARalpha-PLZF overcomes PLZF-mediated repression of CRABPI, contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 104: 18694-18699. *

• Guma M, Salinas I, Reverter JL, Roca J, Valls-Roc M, Juan M, Olive A 2003 Frequency of antineutrophil cytoplasmic antibody in Graves' disease patients treated with methimazole. J. Clin. Endocrinol. Metab. 88: 2141-2146. *

• Haapamaki MM, Gronroos J, Nurmi H, Irjala K, Peuravuori H, Nevalainen TJ 2006 Value of blood tests including serum group IIA phospholipase A2 and bactericidal/permeability-increasing protein in Crohn's disease. Scand. J. Clin. Lab. Invest. 66: 585-594. *

• Haapamaki MM, Haggblom JO, Gronroos JM, Pekkala E, Alanen K, Nevalainen TJ 1999 Bactericidal/permeability-increasing protein in colonic mucosa in ulcerative colitis. Hepatogastroenterology 46: 2273-2277.

• Hamann L, Alexander C, Stamme C, Zahringer U, Schumann RR 2005 Acute-phase concentrations of lipopolysaccharide (LPS)-binding protein inhibit innate immune cell activation by different LPS chemotypes via different mechanisms. Infect. Immun. 73: 193-200. *

• Horwitz AH, Williams RE, Nowakowski G 1995 Human lipopolysaccharide-binding protein potentiates bactericidal activity of human bactericidal/permeability-increasing protein. Infect. Immun. 63: 522-527. *

• Hubacek JA, Stuber F, Frohlich D, Book M, Wetegrove S, Ritter M, Rothe G, Schmitz G 2001 Gene variants of the bactericidal/permeability increasing protein and lipopolysaccharide binding protein in sepsis patients: gender-specific genetic predisposition to sepsis. Crit. Care Med. 29: 557-561.

• in't Veld G, Mannion B, Weiss J, Elsbach P 1988 Effects of the bactericidal/permeability-increasing protein of polymorphonuclear leukocytes on isolated bacterial cytoplasmic membrane vesicles. Infect. Immun. 56: 1203-1208. *

• Iovine NM, Elsbach P, Weiss J 1997 An opsonic function of the neutrophil bactericidal/permeability-increasing protein depends on both its N- and C-terminal domains. Proc. Natl. Acad. Sci. U.S.A. 94: 10973-10978. *

• Jagiello P, Klein W, Schultz H, Csernok E, Gross WL, Epplen JT 2005 Association study of Wegener granulomatosis and the functionally relevant A645G polymorphism in the bactericidal/permeability increasing protein (BPI) gene. Int. J. Immunogenet. 32: 3-6. *

• Jiang J, Zhu P, Wang Z, He Y, Liu D, Tian K, Diao Y 1998 Protective effect of bactericidal/permeability-increasing protein in mice with E. coli sepsis. Chin. J. Traumatol. 1: 21-24.

• Kallenberg CG 1997 Laboratory findings in the vasculitides. Baillieres Clin. Rheumatol. 11: 395-421.

• Khanna D, Aggarwal A, Bhakuni DS, Dayal R, Misra R 2003 Bactericidal/permeability-increasing protein and cathepsin G are the major antigenic targets of antineutrophil cytoplasmic autoantibodies in systemic sclerosis. J. Rheumatol. 30: 1248-1252.

• Kimmings AN, van Deventer SJ, Obertop H, Rauws EA, Huibregtse K, Gouma DJ 2000 Endotoxin, cytokines, and endotoxin binding proteins in obstructive jaundice and after preoperative biliary drainage. Gut 46: 725-731. *

• Kimmings AN, van Deventer SJ, Rauws EAJ, Huibregtse K, Gouma DJ 2000 Systemic inflammatory response in acute cholangitis and after subsequent treatment. Eur. J. Surg. 166: 700-705.

• Kirov G, Lowry CA, Stephens M, Oldfield S, O'Donovan MC, Lightman SL, Owen MJ 2001 Screening ABCG1, the human homologue of the Drosophila white gene, for polymorphisms and association with bipolar affective disorder. Mol. Psychiatry 6: 671-677.

• Klein W, Tromm A, Folwaczny C, Hagedorn M, Duerig N, Epplen J, Schmiegel W, Griga T 2005 A polymorphism of the bactericidal/permeability increasing protein (BPI) gene is associated with Crohn's disease. J. Clin. Gastroenterol. 39: 282-283.

• Kobayashi H 2005 Airway biofilms: implications for pathogenesis and therapy of respiratory tract infections. Treat. Respir. Med. 4: 241-253.

• Kobayashi N, Kiptoo P, Kobayashi H, Ridwan R, Brocke S, Siahaan TJ 2008 Prophylactic and therapeutic suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor. Clin. Immunol. Aug 1 [Epub ahead of print].

• Kobayashi N, Kobayashi H, Gu L, Malefyt T, Siahaan TJ 2007 Antigen-specific suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor. J. Pharmacol. Exp. Ther. 322: 879-886. *

• Kong QL, Guan YZ, Jing XF, Li C, Guo XH, Lu Z, An YQ 2006 BPI700-Fc gamma1(700) chimeric gene expression and its protective effect in a mice model of the lethal E. coli infection. Chin. Med. J. (Engl.) 119: 474-481.

• Lane MA, Xu J, Wilen EW, Sylvester R, Derguini F, Gudas LJ 2008 LIF removal increases CRABPI and CRABPII transcripts in embryonic stem cells cultured in retinol or 4-oxoretinol. Mol. Cell. Endocrinol. 280: 63-74.

• Lennartsson A, Pieters K, Ullmark T, Vidovic K, Gullberg U 2003 AML-1, PU.1, and Sp3 regulate expression of human bactericidal/permeability-increasing protein. Biochem. Biophys. Res. Commun. 311: 853-863. *

• Lennartsson A, Vidovic K, Pass MB, Cowland JB, Gullberg U 2006 All-trans retinoic acid-induced expression of bactericidal/permeability-increasing protein (BPI) in human myeloid cells correlates to binding of C/EBPbeta and C/EBPepsilon to the BPI promoter. J. Leukoc Biol. 80: 196-203. *

• Levin MS, Davis AE 1997 Retinoic acid increases cellular retinol binding protein II mRNA and retinol uptake in the human intestinal Caco-2 cell line. J. Nutr. 127: 13-17. *

• Levy O 2002 Therapeutic potential of the bactericidal/permeability-increasing protein. Expert Opin. Investig. Drugs 11: 159-167.

• Levy O, Canny G, Serhan CN, Colgan SP 2003 Expression of BPI (bactericidal/permeability-increasing protein) in human mucosal epithelia. Biochem. Soc. Trans. 31: 795-800. *

• Levy O, Elsbach P 2001 Bactericidal/permeability-increasing protein in host defense and its efficacy in the treatment of bacterial sepsis. Curr. Infect. Dis. Rep. 3: 407-412.

• Levy O, Martin S, Eichenwald E, Ganz T, Valore E, Carroll SF, Lee K, Goldmann D, Thorne GM 1999 Impaired innate immunity in the newborn: newborn neutrophils are deficient in bactericidal/permeability-increasing protein. Pediatrics 104: 1327-1333. *

• Levy O, Ooi CE, Elsbach P, Doerfler ME, Lehrer RI, Weiss J 1995 Antibacterial proteins of granulocytes differ in interaction with endotoxin. Comparison of bactericidal/permeability-increasing protein, p15s, and defensins. J. Immunol. 154: 5403-5410.

• Levy O, Sisson RB, Kenyon J, Eichenwald E, Macone AB, Goldmann D 2000 Enhancement of neonatal innate defense: effects of adding an N-terminal recombinant fragment of bactericidal/permeability-increasing protein on growth and tumor necrosis factor-inducing activity of gram-negative bacteria tested in neonatal cord blood … Infect. Immun. 68: 5120-5125. *

• Lindgren S, Nilsson S, Nassberger L, Verbaan H, Wieslander J 2000 Anti-neutrophil cytoplasmic antibodies in patients with chronic liver diseases: prevalence, antigen specificity and predictive value for diagnosis of autoimmune liver disease. Swedish Internal Medicine Liver Club (SILK) J. Gastroenterol. Hepatol. 15: 437-442. *

• Linzmeier RM, Ganz T 2006 Copy number polymorphisms are not a common feature of innate immune genes. Genomics 88: 122-126. *

• Locht H, Skogh T, Wiik A 2000 Characterisation of autoantibodies to neutrophil granule constituents among patients with reactive arthritis, rheumatoid arthritis, and ulcerative colitis. Ann. Rheum. Dis. 59: 898-903. *

• Lopez-Valencia V, Rangel P, Rodriguez S, Hernandez-Munoz R 2007 Involvement of alcohol and aldehyde dehydrogenase activities on hepatic retinoid metabolism and its possible participation in the progression of rat liver regeneration. Biochem. Pharmacol. 73: 586-596. *

• Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, Reynolds R, Aloisi F 2007 Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130: 1089-1104.

• Mahadeva R, Dunn AC, Westerbeek RC, Sharples L, Whitehouse DB, Carroll NR, Ross-Russell RI, Webb AK, Bilton D, Lomas DA, Lockwood CM 1999 Anti-neutrophil cytoplasmic antibodies (ANCA) against bactericidal/permeability-increasing protein (BPI) and cystic fibrosis lung disease. Clin. Exp. Immunol. 117: 561-567. *

• Mahadeva R, Zhao MH, Stewart S, Cary N, Flower C, Lockwood M, Shneerson J 1997 Vasculitis and bronchiectasis in a patient with antibodies to bactericidal/permeability-increasing protein and alpha1-antitrypsin deficiency. Chest 112: 1699-1701. *

• Malenica B, Rudolf M, Kozmar A 2004 Antineutrophil cytoplasmic antibodies (ANCA): diagnostic utility and potential role in the pathogenesis of vasculitis. Acta Dermatovenerol. Croat. 12: 294-313.

• Mangelsdorf DJ, Umesono K, Kliewer SA, Borgmeyer U, Ong ES, Evans RM 1991 A direct repeat in the cellular retinol-binding protein type II gene confers differential regulation by RXR and RAR. Cell 66: 555-561. *

• Mannion BA, Kalatzis ES, Weiss J, Elsbach P 1989 Preferential binding of the neutrophil cytoplasmic granule-derived bactericidal/permeability increasing protein to target bacteria. Implications and use as a means of purification. J. Immunol. 142: 2807-2812.

• Manolova I, Dancheva M, Halacheva K 2001 Antineutrophil cytoplasmic antibodies in patients with systemic lupus erythematosus: prevalence, antigen specificity, and clinical associations. Rheumatol. Int. 20: 197-204. *

• Marangell LB, Suppes T, Ketter TA, Dennehy EB, Zboyan H, Kertz B, Nierenberg A, Calabrese J, Wisniewski SR, Sachs G 2006 Omega-3 fatty acids in bipolar disorder: clinical and research considerations. Prostaglandins Leukot. Essent. Fatty Acids 75: 315-321. *

• Marra MN, Thornton MB, Snable JL, Leong S, Lane J, Wilde CG, Scott RW 1993 Regulation of the response to bacterial lipopolysaccharide by endogenous and exogenous lipopolysaccharide binding proteins. Blood Purif. 11: 134-140.

• Marra MN, Wilde CG, Griffith JE, Snable JL, Scott RW 1990 Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity. J. Immunol. 144: 662-666.

• Matsuyama W, Wakimoto J, Watanabe A, Kubota I, Hirotsu Y, Mizoguchi A, Iwami F, Kawabata M, Osame M 1999 Bronchiectasis with myeloperoxidase antineutrophil cytoplasmic antibody and bactericidal/permeability-increasing protein antineutrophil cytoplasmic antibody. Intern. Med. 38: 813-816. *

• Mayo KH, Haseman J, Ilyina E, Gray B 1998 Designed beta-sheet-forming peptide 33mers with potent human bactericidal/permeability increasing protein-like bactericidal and endotoxin neutralizing activities. Biochim. Biophys. Acta 1425: 81-92. *

• McInnis MG, Lan TH, Willour VL, McMahon FJ, Simpson SG, Addington AM, MacKinnon DF, Potash JB, Mahoney AT, Chellis J, Huo Y, Swift-Scanlan T, Chen H, Koskela R, Stine OC, Jamison KR, Holmans P, Folstein SE, Ranade K, Friddle C, Botstein D, Marr T, et al 2003 Genome-wide scan of bipolar disorder in 65 pedigrees: supportive evidence for linkage at 8q24, 18q22, 4q32, 2p12, and 13q12. Mol. Psychiatry 8: 288-298. *

• Merkler D, Ernsting T, Kerschensteiner M, Bruck W, Stadelmann C 2006 A new focal EAE model of cortical demyelination: multiple sclerosis-like lesions with rapid resolution of inflammation and extensive remyelination. Brain 129: 1972-1983. *

• Michalek J, Svetlikova P, Fedora M, Klimovic M, Klapacova L, Bartosova D, Elbl L, Hrstkova H, Hubacek JA 2007 Bactericidal permeability increasing protein gene variants in children with sepsis. Intensive Care Med. 33: 2158-2164. *

• Mochizuki K, Mochizuki H, Kawai H, Ogura Y, Shimada M, Takase S, Goda T 2008 Possible role of fatty acids in milk as the regulator of the expression of cytosolic binding proteins for fatty acids and vitamin A through PPARalpha in developing rats. J. Nutr. Sci. Vitaminol. (Tokyo) 53: 515-521. *

• Mochizuki K, Suruga K, Kitagawa M, Takase S, Goda T 2001 Modulation of the expression of peroxisome proliferator-activated receptor-dependent genes through disproportional expression of two subtypes in the small intestine. Arch. Biochem. Biophys. 389: 41-48. *

• Monajemi H, Meenan J, Lamping R, Obradov DO, Radema SA, Trown PW, Tytgat GN, Van Deventer SJ 1996 Inflammatory bowel disease is associated with increased mucosal levels of bactericidal/permeability-increasing protein. Gastroenterology 110: 733-739. *

• Muller CA, Autenrieth IB, Peschel A 2005 Intestinal epithelial barrier and mucosal immunity innate defenses of the intestinal epithelial barrier. Cell. Mol. Life Sci. 62: 1297-1307. *

• Nakamura K, Inoue I, Takahashi S, Komoda T, Katayama S 2008 Cryptochrome and period proteins are regulated by the CLOCK/BMAL1 gene: crosstalk between the PPARs/RXRalpha-regulated and CLOCK/BMAL1-regulated systems. PPAR Res. 2008: 348610. *

• Nalbandian A, Pang AL, Rennert OM, Chan WY, Ravindranath N, Djakiew D 2005 A novel function of differentiation revealed by cDNA microarray profiling of p75-regulated gene expression. Differentiation 73: 385-396. *

• Nishimura H, Gogami A, Miyagawa Y, Nanbo A, Murakami Y, Baba T, Nagasawa S 2001 Bactericidal/permeability-increasing protein promotes complement activation for neutrophil-mediated phagocytosis on bacterial surface. Immunology 103: 519-525. *

• Nupponen I, Turunen R, Nevalainen T, Peuravuori H, Pohjavuori M, Repo H, Andersson S 2002 Extracellular release of bactericidal/permeability-increasing protein in newborn infants. Pediatr. Res. 51: 670-674. *

• O'Byrne SM, Wongsiriroj N, Libien J, Vogel S, Goldberg IJ, Baehr W, Palczewski K, Blaner WS 2005 Retinoid absorption and storage is impaired in mice lacking lecithin:retinol acyltransferase (LRAT). J. Biol. Chem. 280: 35647-35657. *

• Ohtami S, Kobayashi O, Ohtami H 2001 Analysis of intractable factors in chronic airway infections: role of the autoimmunity induced by BPI-ANCA. J. Infect. Chemother. 7: 228-238.

• Ooi CE, Weiss J, Doerfler ME, Elsbach P 1991 Endotoxin-neutralizing properties of the 25 kD N-terminal fragment and a newly isolated 30 kD C-terminal fragment of the 55-60 kD bactericidal/permeability-increasing protein of human neutrophils. J. Exp. Med. 174: 649-655. *

• Paulsen F, Pufe T, Conradi L, Varoga D, Tsokos M, Papendieck J, Petersen W 2002 Antimicrobial peptides are expressed and produced in healthy and inflamed human synovial membranes. J. Pathol. 198: 369-377. *

• Pineau BC, Paskett ED, Chen GJ, Espeland MA, Phillips K, Han JP, Mikulaninec C, Vining DJ 2003 Virtual colonoscopy using oral contrast compared with colonoscopy for the detection of patients with colorectal polyps. Gastroenterology 125: 304-310. *

• Pomeroy IM, Jordan EK, Frank JA, Matthews PM, Esiri MM 2008 Diffuse cortical atrophy in a marmoset model of multiple sclerosis. Neurosci. Lett. 437: 121-124.

• Radice A, Vecchi M, Bianchi MB, Sinico RA 2000 Contribution of immunofluorescence to the identification and characterization of anti-neutrophil cytoplasmic autoantibodies. The role of different fixatives. Clin. Exp. Rheumatol. 18: 707-712.

• Reichel PH, Seemann C, Csernok E, Schroder JM, Muller A, Gross WL, Schultz H 2003 Bactericidal/permeability-increasing protein is expressed by human dermal fibroblasts and upregulated by interleukin 4. Clin. Diagn. Lab. Immunol. 10: 473-475. *

• Rennekampff OH, Tenenhaus M, Hansbrough J, Kiessig V, Zapata-Sirvent RL 1997 Effects of recombinant bactericidal, permeability-increasing protein on bacterial translocation and pulmonary neutrophil sequestration in burned mice. J. Burn Care Rehabil. 18: 17-21.

• Romand R, Dolle P, Hashino E 2006 Retinoid signaling in inner ear development. J. Neurobiol. 66: 687-704. *

• Roozendaal C, Van Milligen de Wit AW, Haagsma EB, Horst G, Schwarze C, Peter HH, Kleibeuker JH, Tervaert JW, Limburg PC, Kallenberg CG 1998 Antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: defined specificities may be associated with distinct clinical features. Am. J. Med. 105: 393-399. *

• Roozendaal C, Zhao MH, Horst G, Lockwood CM, Kleibeuker JH, Limburg PC, Nelis GF, Kallenberg CG 1998 Catalase and alpha-enolase: two novel granulocyte autoantigens in inflammatory bowel disease (IBD). Clin. Exp. Immunol. 112: 10-16. *

• Rossini M, Viapiana O, Del Marco A, de Terlizzi F, Gatti D, Adami S 2007 Quantitative ultrasound in adults with cystic fibrosis: correlation with bone mineral density and risk of vertebral fractures. Calcif. Tissue Int. 80: 44-49. *

• Rotschild M, Elias N, Berkowitz D, Pollak S, Shinawi M, Beck R, Bentur L 2005 Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin. Clin. Exp. Med. 5: 80-85. *

• Savige J, Nassis L, Cooper T, Paspaliaris B, Martinello P, MacGregor D 2002 Antineutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis after immunisation with bacterial proteins. Clin. Exp. Rheumatol. 20: 783-789.

• Savige JA, Chang L, Wilson D, Buchanan RR 1996 Autoantibodies and target antigens in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides. Rheumatol. Int. 16: 109-114.

• Savige JA, Paspaliaris B, Silvestrini R, Davies D, Nikoloutsopoulos T, Sturgess A, Neil J, Pollock W, Dunster K, Hendle M 1998 A review of immunofluorescent patterns associated with antineutrophil cytoplasmic antibodies (ANCA) and their differentiation from other antibodies. J. Clin. Pathol. 51: 568-575. *

• Sawa T, Kurahashi K 1999 Antimicrobial peptides/proteins - application to the therapy of sepsis. Masui 48: 1186-1193.

• Schinke S, Fellermann K, Herlyn K, Reichel PH, Fundke R, Stange EF, Gross WL, Schultz H 2004 Autoantibodies against the bactericidal/permeability-increasing protein from inflammatory bowel disease patients can impair the antibiotic activity of bactericidal/permeability-increasing protein. Inflamm. Bowel Dis. 10: 763-770. *

• Schnabel A, Csernok E, Schultz H, Stoffel M, Herzberg C, Carroll SF, Gross WL 1997 Bactericidal permeability increasing protein (BPI-ANCA) marked chronic inflammatory bowel diseases and hepatobiliary diseases. Med. Klin. 92: 389-393.

• Schultz H 2007 From infection to autoimmunity: a new model for induction of ANCA against the bactericidal/permeability increasing protein (BPI). Autoimmun. Rev. 6: 223-227.

• Schultz H, Csernok E, Herlyn K, Reichel PH, Moosig F, Cornely OA, Fagerhol MK, Gross WL 2003 ANCA against bactericidal/permeability-increasing protein, azurocidin, calprotectin and defensins in rheumatic and infectious diseases: prevalence and clinical associations. Clin. Exp. Rheumatol. 21 (6 Suppl. 32): S117-S120.

• Schultz H, Csernok E, Johnston TW, Lockwood CM, Gross WL 1997 Use of native and recombinant bactericidal/permeability-increasing proteins (BPI) as antigens for detection of BPI-ANCA. J. Immunol. Methods 205: 127-133. *

• Schultz H, Csernok E, Nikkari S, Toivanen P, Toivanen A, Gross WL 2000 BPI-ANCA is found in reactive arthritis caused by Yersinia and Salmonella infection and recognise exclusively the C-terminal part of the BPI molecule. Scand. J. Rheumatol. 29: 226-231.

• Schultz H, Csernok E, Schuster A, Schmitz TS, Ernst M, Gross WL 2000 Anti-neutrophil cytoplasmic antibodies directed against the bactericidal/permeability-increasing protein (BPI) in pediatric cystic fibrosis patients do not recognize N-terminal regions important for the anti-microbial and lipopolysaccharide-binding … Pediatr. Allergy Immunol. 11: 64-70. *

• Schultz H, Heintz H, van Zandbergen G, Ullrich S, Reinhold-Keller E, Gross WL 2003 ANCA against the bactericidal/permeability increasing protein (BPI-ANCA) can compromise the antibiotic function of BPI in a Wegener's granulomatosis patient. Clin. Exp. Rheumatol. 21: 763-766.

• Schultz H, Schinke S, Mosler K, Herlyn K, Schuster A, Gross WL 2004 BPI-ANCA of pediatric cystic fibrosis patients can impair BPI-mediated killing of E. coli DH5alpha in vitro. Pediatr. Pulmonol. 37: 158-164.

• Schultz H, Schinke S, Weiss J, Cerundolo V, Gross WL, Gadola S 2003 BPI-ANCA in transporter associated with antigen presentation (TAP) deficiency: possible role in susceptibility to Gram-negative bacterial infections. Clin. Exp. Immunol. 133: 252-259. *

• Schultz H, Weiss J, Carroll SF, Gross WL 2001 The endotoxin-binding bactericidal/permeability-increasing protein (BPI): a target antigen of autoantibodies. J. Leukoc. Biol. 69: 505-512. *

• Schultz H, Weiss JP 2007 The bactericidal/permeability-increasing protein (BPI) in infection and inflammatory disease. Clin. Chim. Acta 384: 12-23. *

• Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, Mathison JC, Tobias PS, Ulevitch RJ 1990 Structure and function of lipopolysaccharide binding protein. Science 249: 1429-1431. *

• Sediva A, Bartunkova J, Bartosova J, Jennette C, Falk RJ, Jethwa HS 2003 Antineutrophil cytoplasmic antibodies directed against bactericidal/permeability-increasing protein detected in children with cystic fibrosis inhibit neutrophil-mediated killing of Pseudomonas aeruginosa. Microbes Infect. 5: 27-30. *

• Sediva A, Bartunkova J, Kolarova I, Hrusak O, Vavrova V, Macek M Jr, Lockwood CM, Dunn AC 1998 Antineutrophil cytoplasmic autoantibodies (ANCA) in children with cystic fibrosis. J. Autoimmun. 11: 185-190.

• Sediva A, Kolarova I, Bartunkova J 1998 Antineutrophil cytoplasmic antibodies in children. Eur. J. Pediatr. 157: 987-991. *

• So PL, Fujimoto MA, Epstein EH Jr 2008 Pharmacologic retinoid signaling and physiologic retinoic acid receptor signaling inhibit basal cell carcinoma tumorigenesis. Mol. Cancer Ther. 7: 1275-1284.

• Stack AM, Saladino RA, Siber GR, Thompson C, Marra MN, Novitsky TJ, Fleisher GR 1997 A comparison of bactericidal/permeability-increasing protein variant versus recombinant endotoxin-neutralizing protein for the treatment of Escherichia coli sepsis in rats. Crit. Care Med. 25: 101-105.

• Stoffel MP, Csernok E, Herzberg C, Johnson T, Carroll SF, Gross WL 1996 Anti-neutrophil cytoplasmic antibodies (ANCA) directed against bactericidal/permeability increasing protein (BPI): a new seromarker for inflammatory bowel disease and associated disorders. Clin. Exp. Immunol. 104: 54-59. *

• Suruga K, Mochizuki K, Suzuki R, Goda T, Takase S 1999 Regulation of cellular retinol-binding protein type II gene expression by arachidonic acid analogue and 9-cis retinoic acid in Caco-2 cells. Eur. J. Biochem. 262: 70-78.

• Taccetti G, Campana S, Marianelli L, Procopio E, Turchini S 1999 Autoantibodies against bactericidal/permeability-increasing protein in cystic fibrosis patients: comment on the article by Hoffman and Specks. Arthritis Rheum. 42: 1305-1306. *

• Taddei C, Audrain MA, Reumaux D, Sesboue R, Testa A, Galmiche JP, Duthilleul P, Colombel JF, Esnault VL 1999 Alpha1-antitrypsin phenotypes and anti-neutrophil cytoplasmic auto-antibodies in inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 11: 1293-1298.

• Takahashi M, Horiuchi Y, Tezuka T 2004 Presence of bactericidal/permeability-increasing protein in human and rat skin. Exp. Dermatol. 13: 55-60. *

• Takase S, Suruga K, Goda T 2000 Regulation of vitamin A metabolism-related gene expression. Br. J. Nutr. 84 Suppl. 2: S217-S221.

• Teixeira L, Mahr A, Jaureguy F, Noel LH, Nunes H, Lefort A, Barry S, Deny P, Guillevin L 2005 Low seroprevalence and poor specificity of antineutrophil cytoplasmic antibodies in tuberculosis. Rheumatology (Oxford) 44: 247-250. *

• Torok HP, Glas J, Tonenchi L, Mussack T, Folwaczny C 2004 Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin. Immunol. 112: 85-91. *

• van Leeuwen HJ, Van Der Tol M, Van Strijp JA, Verhoef J, van Kessel KP 2005 The role of tumour necrosis factor in the kinetics of lipopolysaccharide-mediated neutrophil priming in whole blood. Clin. Exp. Immunol. 140: 65-72. *

• Vecchi M, Sinico A, Bianchi MB, Radice A, Gionchetti P, Campieri M, de Franchis R 1998 Recognition of bactericidal/permeability-increasing protein by perinuclear anti-neutrophil cytoplasmic antibody-positive sera from ulcerative colitis patients: prevalence and clinical significance. Scand. J. Gastroenterol. 33: 1284-1288. *

• Verhoef J, Hustinx WM, Frasa H, Hoepelman AI 1996 Issues in the adjunct therapy of severe sepsis. J. Antimicrob. Chemother. 38: 167-182.

• Vierling JM 2003 Is primary sclerosing cholangitis an autoimmune disease? Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 67-69. October 15-16. *

• Walmsley RS, Zhao MH, Hamilton MI, Brownlee A, Chapman P, Pounder RE, Wakefield AJ, Lockwood CM 1997 Antineutrophil cytoplasm autoantibodies against bactericidal/permeability-increasing protein in inflammatory bowel disease. Gut 40: 105-109. *

• Weiss J 2003 Bactericidal/permeability-increasing protein (BPI) and lipopolysaccharide-binding protein (LBP): structure, function and regulation in host defence against Gram-negative bacteria. Biochem. Soc. Trans. 31: 785-790. *

• Weiss J, Elsbach P, Shu C, Castillo J, Grinna L, Horwitz A, Theofan G 1992 Human bactericidal/permeability-increasing protein and a recombinant NH2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria. J. Clin. Invest. 90: 1122-1130. *

• Weiss J, Muello K, Victor M, Elsbach P 1984 The role of lipopolysaccharides in the action of the bactericidal/permeability-increasing neutrophil protein on the bacterial envelope. J. Immunol. 132: 3109-3115.

• Weiss J, Olsson I 1987 Cellular and subcellular localization of the bactericidal/permeability-increasing protein of neutrophils. Blood 69: 652-659. *

• Werman A, Werman-Venkert R, White R, Lee JK, Werman B, Krelin Y, Voronov E, Dinarello CA, Apte RN 2004 The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. Proc. Natl. Acad. Sci. U.S.A. 101: 2434-2439. *

• Wiese A, Brandenburg K, Carroll SF, Rietschel ET, Seydel U 1997 Mechanisms of action of bactericidal/permeability-increasing protein BPI on reconstituted outer membranes of gram-negative bacteria. Biochemistry 36: 10311-10319. *

• Wiese A, Brandenburg K, Lindner B, Schromm AB, Carroll SF, Rietschel ET, Seydel U 1997 Mechanisms of action of the bactericidal/permeability-increasing protein BPI on endotoxin and phospholipid monolayers and aggregates. Biochemistry 36: 10301-10310. *

• Wiese A, Gutsmann T, Seydel U 2003 Towards antibacterial strategies: studies on the mechanisms of interaction between antibacterial peptides and model membranes. J. Endotoxin Res. 9: 67-84.

• Wiezer MJ, Boelens PG, Vuylsteke RJ, Nijveldt RJ, Meijer C, Cuesta MA, Meijer S, van Leeuwen PA 2001 Perioperative treatment with bactericidal/permeability-increasing protein (rBPI21) in major liver surgery: a concise summary. Ann. Acad. Med. Singapore 30: 226-233.

• Wiezer MJ, Langendoen SI, Meijer C, Bauer RJ, White ML, Carroll SF, Meyer S, Thijs LG, van Leeuwen PA 1998 Pharmacokinetics of a recombinant amino terminal fragment of bactericidal/permeability increasing protein (rBPI21) after liver surgery in rats and humans. Shock 10: 161-166.

• Xiao JH, Durand B, Chambon P, Voorhees JJ 1995 Endogenous retinoic acid receptor (RAR)-retinoid X receptor (RXR) heterodimers are the major functional forms regulating retinoid-responsive elements in adult human keratinocytes. Binding of ligands to RAR only is sufficient for RAR-RXR heterodimers … J. Biol. Chem. 270: 3001-3011. *

• Xin G, Zhao MH, Wang HY 2004 Detection rate and antigenic specificities of antineutrophil cytoplasmic antibodies in Chinese patients with clinically suspected vasculitis. Clin. Diagn. Lab. Immunol. 11: 559-562. *

• Yamaguchi N, Suruga K 2008 Triiodothyronine stimulates CMO1 gene expression in human intestinal Caco-2 BBe cells. Life Sci. 82: 789-796. *

• Yang JJ, Tuttle R, Falk RJ, Jennette JC 1996 Frequency of anti-bactericidal/permeability-increasing protein (BPI) and anti-azurocidin in patients with renal disease. Clin. Exp. Immunol. 105: 125-131. *

• Zhai Y, Qiao B, Shen XD, Gao F, Busuttil RW, Cheng G, Platt JL, Volk HD, Kupiec-Weglinski JW 2008 Evidence for the pivotal role of endogenous Toll-like receptor 4 ligands in liver ischemia and reperfusion injury. Transplantation 85: 1016-1022.

• Zhang LT, Yao YM, Lu JQ, Yan XJ, Yu Y, Sheng ZY 2008 Recombinant bactericidal/permeability-increasing protein inhibits endotoxin-induced high-mobility group box 1 protein gene expression in sepsis. Shock 29: 278-284.

• Zhao MH, Jayne DR, Ardiles LG, Culley F, Hodson ME, Lockwood CM 1996 Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis. QJM 89: 259-265.

• Zhao MH, Jones SJ, Lockwood CM 1995 Bactericidal/permeability-increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis. Clin. Exp. Immunol. 99: 49-56. *

• Zhao MH, Lockwood CM 1996 A comprehensive method to purify three major ANCA antigens: proteinase 3, myeloperoxidase and bactericidal/permeability-increasing protein from human neutrophil granule acid extract. J. Immunol. Methods 197: 121-130.

• Zhou H 2001 A study on bactericidal/permeability increasing protein (BPI) as a natural inhibitor of endotoxin. Zhonghua Shao Shang Za Zhi 17: 102-104.

Number of references = 185

www psc-literature.org